Rising Up
- Conditions
- Atopic Dermatitis
- Registration Number
- JPRN-jRCT2080224059
- Lead Sponsor
- AbbVie GK
- Brief Summary
The benefit-risk profile of both doses of upadacitinib in this study is assessed as favorable based on the safety and exploratory efficacy outcomes of the study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 272
Active moderate to severe atopic dermatitis defined by Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Body surface area (BSA), and pruritus.
-Candidate for systemic therapy or have recently required systemic therapy for atopic dermatitis.
-Able to tolerate topical corticosteroids for atopic dermatitis lesions.
- Prior exposure to any Janus kinase (JAK) inhibitor
- Unable or unwilling to discontinue current atopic dermatitis (AD) treatments prior to the study
- Requirement of prohibited medications during the study
- Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions
- Female subject who is pregnant, breastfeeding, or considering pregnancy during the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety<br>Number of participants experiencing adverse events
- Secondary Outcome Measures
Name Time Method safety<br>-